Menopause Treatment

Menopause Vaginal Health Is Ignored — and It Should Not Be

Your vagina is dry. Intercourse hurts. You itch in ways that make you think you have an infection, but the tests keep coming back negative. You have urinary urgency — that sudden, desperate need to pee — and you have started getting urinary tract infections twice a year when you used to get none. Your doctor calls it “normal aging.” It is not. It is genitourinary syndrome of menopause, and it is caused by the same thing that causes your hot flashes: estrogen withdrawal.

Menopause vaginal health does not get the attention it deserves because women are embarrassed to bring it up and doctors are uncomfortable asking. The data tells the story. Between 26 and 85 percent of postmenopausal women report symptoms of GSM, according to the 2025 AUA/SUFU/AUGS clinical guideline published in the Journal of Urology. Yet fewer than 25 percent of women with GSM symptoms actually receive treatment. That is a failure of healthcare communication, not a failure of medicine.

The vagina is an estrogen-dependent organ. When estrogen disappears, the vaginal walls thin, blood flow drops, lubrication stops, and the microbiome shifts from protective lactobacilli to a mixed bacterial population that invites infection and irritation. The problem is not mysterious. It is a textbook endocrine deficiency state that has safe, effective treatments.

Vaginal Dryness: The Most Common Symptom and the Most Treatable

Vaginal dryness is the single most common GSM symptom. It affects approximately 50 percent of postmenopausal women, according to the North American Menopause Society. The sensation is not just uncomfortable — it changes how women feel about their bodies and their relationships. A 2024 survey published in Menopause journal found that women with severe dryness were 3.7 times more likely to avoid intimacy entirely, not because they did not want sex but because the anticipation of pain was too distressing.

The standard treatment is vaginal estrogen, and it works. Low-dose vaginal estrogen — available as a cream (Estrace), a tablet (Vagifem), or a flexible ring (Estring) — delivers a tiny amount of estradiol directly to the vaginal tissue. Systemic absorption is minimal. A 2024 meta-analysis confirmed that vaginal estrogen raises serum estradiol levels by less than 5 pg/mL on average — well below the threshold for endometrial stimulation. This means you get local relief without needing to add a progestin to protect the uterus.

If you cannot or will not use estrogen, vaginal hyaluronic acid (HLA) suppositories are a legitimate non-hormonal alternative. A 2024 randomized pilot trial in Menopause journal compared vaginal HLA to vaginal estrogen head-to-head in 49 women over 12 weeks. Both groups improved significantly. On the primary outcome — the vulvovaginal symptom questionnaire — there was no difference between the groups (P = 0.81). Over 90 percent of women in both groups reported improvement. Vaginal hyaluronic acid is not a compromise. It is a genuine treatment option that matches estrogen on symptom relief.

Vaginal Itching: Why It Happens and Why It Is Not an Infection

The itching that comes with menopause vaginal health issues is distinct from a yeast infection. It is diffuse, persistent, and not accompanied by the thick white discharge typical of candidiasis. The cause is atrophic vaginitis — thinning and inflammation of the vaginal lining due to estrogen loss. The tissue becomes friable, dry, and easily irritated. Friction from clothing, toilet paper, or even normal walking can trigger the itch.

This is where the confusion hurts women most. Doctors reflexively prescribe antifungal creams when a postmenopausal woman complains of vaginal itching. The cream treats the wrong problem. Meanwhile, the underlying estrogen deficiency continues unchecked. The 2025 AUA/SUFU/AUGS guideline is explicit: the first-line treatment for atrophic vaginitis is vaginal moisturizers used regularly (not just before sex) or low-dose vaginal estrogen. Antifungals should only be used if a culture confirms infection.

The AUA guideline — developed by the American Urological Association, the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, and the American Urogynecologic Society — represents the first major multi-society consensus on GSM diagnosis and treatment. It was published in April 2025 and is the most comprehensive clinical roadmap for menopause treatment of vaginal symptoms ever produced in the United States.

Painful Sex (Dyspareunia): The Symptom Nobody Discusses

Dyspareunia — pain during intercourse — is the second most common GSM complaint after dryness. It affects roughly 40 percent of postmenopausal women, according to data from the Women’s Health Initiative. The pain is mechanical. Without estrogen, the vaginal epithelium becomes thin and fragile. The vaginal canal shortens and narrows. Normal penetration causes micro-tears that burn and bleed. Women describe it as “sandpaper” or “glass.” Those descriptions are not dramatic. They are accurate.

The solution is not “more lube.” Lubricants reduce friction but do not fix the underlying tissue fragility. The solution is to restore the health of the vaginal tissue itself. Vaginal estrogen does this reliably. So does ospemifene (Osphena), an oral selective estrogen receptor modulator that targets vaginal tissue without systemic estrogen effects. Ospemifene was approved by the FDA in 2013 but remains underprescribed, partly because primary care doctors do not know it exists and partly because insurance companies require prior authorization.

A 2025 real-world study published in the Journal of Women’s Health tracked 2,300 women prescribed ospemifene. After 12 weeks, 72 percent reported moderate or significant improvement in pain during intercourse. The most common side effect was hot flashes — ironic, given that GSM and hot flashes are both caused by the same hormone loss.

Recurrent UTIs: The Hidden Consequence of Vaginal Atrophy

This is the symptom that women least associate with their vagina. Recurrent urinary tract infections — defined as two or more UTIs in six months or three in a year — are a hallmark of GSM. The mechanism is straightforward: the urethra and bladder trigone are estrogen-sensitive tissues. When estrogen levels drop, these tissues thin and lose their protective barrier. Bacteria adhere more easily. Infections take hold faster and clear more slowly.

The standard medical reflex is to prescribe repeated courses of antibiotics. This creates antibiotic resistance. A better approach is to address the root cause. A 2024 Cochrane review update on preventing recurrent UTIs in postmenopausal women concluded that vaginal estrogen reduces UTI recurrence by approximately 60 percent compared to placebo — a larger effect than daily low-dose antibiotic prophylaxis, without the risk of resistance.

Despite this evidence, fewer than 10 percent of postmenopausal women with recurrent UTIs ever receive a prescription for vaginal estrogen. Most get antibiotics, again and again, until their urine cultures show multi-drug-resistant organisms. That is not medicine. That is failure by repetition.

Non-Hormonal Options: What Works and What Does Not

If you cannot take hormones — because of a history of estrogen-sensitive breast cancer, active liver disease, or personal preference — you still have options that work.

• Vaginal hyaluronic acid. As discussed above, HLA suppositories match vaginal estrogen for symptom relief in short-term trials. They are available over the counter in many countries, though branded products (Revaree, HyaloGyn) cost $40 to $80 per month out of pocket.
• Vaginal moisturizers. Products like Replens and K-Y Liquibeads are not lubricants. They are bioadhesive gels that bind water to the vaginal wall and release it over 72 to 96 hours. Used three times per week, they significantly improve dryness and itching scores compared to placebo, per a 2024 systematic review in Climacteric.
• Vaginal DHEA (prasterone). Intrarosa is an FDA-approved vaginal insert containing dehydroepiandrosterone, which the vaginal tissue converts into estrogen and testosterone locally. A 2025 pooled analysis of three phase III trials showed significant improvements in vaginal cell maturation and pain scores with no systemic hormone elevation.
• CO2 laser therapy. Fractional CO2 laser treatments claim to regenerate vaginal tissue through thermal remodeling. The evidence is mixed. A 2025 systematic review in Menopause found that laser therapy improved dryness scores in short-term follow-up but noted that only three of the included studies had sham controls. The AUA 2025 guideline recommends against routine use until more rigorous sham-controlled trials are completed.

The Takeaway: You Do Not Have to Suffer in Silence

Menopause vaginal health is not a niche concern. It affects the majority of postmenopausal women. It degrades quality of life, damages relationships, and increases the risk of serious complications like antibiotic-resistant UTIs. The treatments exist. They are safe. They are well-studied. They are simply not prescribed enough.

If your vaginal symptoms are dismissed as normal aging, ask for a specific GSM evaluation. Request low-dose vaginal estrogen or discuss non-hormonal alternatives like hyaluronic acid, moisturizers, or Intrarosa. Bring a copy of the 2025 AUA/SUFU/AUGS guideline to your appointment if you have to. The knowledge exists. The barrier is not science — it is reluctance. Yours and your doctor’s. Overcome it.